AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 394870 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP (cyclophosphamide, 5-fluorouracil, and prednisone)
Number of subjects: 71
Study 394870 — intervention group
Group type: COMPARATOR
Intervention: CFP + MER (methanol-extracted residue of Bacillus Calmette-Guerin)
Number of subjects: 71
Study 28923093 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanitation intervention
Number of subjects: 720
Study 28923093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 720
Study 26420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 130
Study 26420261 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GA and IS samples
Number of subjects: 130
Study 26420261 — intervention group
Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 130
Study 26420261 — intervention group
Group type: COMPARATOR
Intervention: BACTEC-MGIT culture
Number of subjects: 130
Study 26420261 — intervention group
Group type: EXPERIMENTAL
Intervention: GA samples
Number of subjects: 130
Study 26420261 — intervention group
Group type: EXPERIMENTAL
Intervention: IS samples
Number of subjects: 130
Study 23566774 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 23566774 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone without CBI
Number of subjects: 0
Study 23566774 — intervention group
Group type: COMPARATOR
Intervention: Placebo naltrexone
Number of subjects: 0
Study 21123958 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping training program with 14 weekly two-hour sessions
Number of subjects: 396
Study 21123958 — intervention group
Group type: COMPARATOR
Intervention: Normal work (control group)
Number of subjects: 396
Study 19137459 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical dimethyl sulfoxide (DMSO)
Number of subjects: 151
Study 19137459 — intervention group
Group type: COMPARATOR
Intervention: Bacille Calmette-Guerin (BCG)
Number of subjects: 151
Study 19137459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine A (CyA)
Number of subjects: 151
Study 19137459 — intervention group
Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 151
Study 17254598 — intervention group
Group type: EXPERIMENTAL
Intervention: Native QRS width in second-degree AV block group
Number of subjects: 50
Study 17254598 — intervention group
Group type: EXPERIMENTAL
Intervention: Native QRS width in total AV block group
Number of subjects: 50
Study 15126758 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (3 month course of a macrolide antibiotic, douche, and topical steroid)
Number of subjects: 90
Study 15126758 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 90
Study 11787915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (500 microg)
Number of subjects: 40
Study 11787915 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Syntocinon (10 iu)
Number of subjects: 40
Study 9470910 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluconolactone (GLU)
Number of subjects: 11
Study 9470910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartaric acid (TA)
Number of subjects: 11
Study 9470910 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA)
Number of subjects: 11
Study 9470910 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (VE)
Number of subjects: 11
Study 9470910 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (UNT)
Number of subjects: 11
Study 8196432 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary functional treatment without external or internal stabilization
Number of subjects: 70
Study 3069522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 80
Study 3069522 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 80
Study 31728714 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day for 11 days)
Number of subjects: 16
Study 31728714 — intervention group
Group type: COMPARATOR
Intervention: Lorlatinib alone (50 mg, 75 mg, 100 mg)
Number of subjects: 16
Study 30816025 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 30
Study 30816025 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 30
Study 28525543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructan (12 g/d)
Number of subjects: 32
Study 28525543 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo (12 g/d)
Number of subjects: 32
Study 28525543 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS, 6 g/d)
Number of subjects: 32
Study 28525543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (6 g/d)
Number of subjects: 32
Study 26204908 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 4282
Study 26204908 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported walking activity
Number of subjects: 4282
Study 26204908 — intervention group
Group type: COMPARATOR
Intervention: Objectively measured ambulatory activity
Number of subjects: 4282
Study 26204908 — intervention group
Group type: COMPARATOR
Intervention: Time spent in MVPA (objectively measured)
Number of subjects: 4282
Study 26204908 — intervention group
Group type: COMPARATOR
Intervention: Self-reported MVPA
Number of subjects: 4282
Study 23945113 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy with mobile VAC Freedom device
Number of subjects: 19
Study 23945113 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing after simple excision
Number of subjects: 19
Study 21808761 — intervention group
Group type: EXPERIMENTAL
Intervention: Human dermis graft (HDG)
Number of subjects: 42
Study 21808761 — intervention group
Group type: COMPARATOR
Intervention: Autogenous connective tissue graft (ACT)
Number of subjects: 42
Study 19299839 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais intervention (twice‐weekly group classes over 8 weeks)
Number of subjects: 55
Study 19299839 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 55
Study 17520889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0
Study 17520889 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0
Study 15355387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark coronal discoloration
Number of subjects: 97
Study 11772893 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated personalized report intervention
Number of subjects: 150
Study 11772893 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 150
Study 11772893 — intervention group
Group type: COMPARATOR
Intervention: Control group (among patients experiencing a decline)
Number of subjects: 150
Study 11772893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (among patients experiencing a decline)
Number of subjects: 150
Study 9843010 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I compression stockings (18 to 26 mm Hg)
Number of subjects: 11
Study 9843010 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II compression stockings (26 to 36 mm Hg)
Number of subjects: 11
Study 9843010 — intervention group
Group type: COMPARATOR
Intervention: Class I and II compression stockings
Number of subjects: 11
Study 8582812 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact Therapeutic Touch
Number of subjects: 0
Study 8582812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2772103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (125 mg) followed by a second dose of caffeine
Number of subjects: 10
Study 2772103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 73429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests with food extracts (1:20 w/v concentration)
Number of subjects: 0
Study 73429 — intervention group
Group type: COMPARATOR
Intervention: Double-blind food challenge
Number of subjects: 0
Study 73429 — intervention group
Group type: COMPARATOR
Intervention: In vitro release of histamine from leucocytes
Number of subjects: 0
Study 30963460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid-mental distance-based group
Number of subjects: 74
Study 30963460 — intervention group
Group type: COMPARATOR
Intervention: Weight-based group
Number of subjects: 74
Study 28678952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (S1)
Number of subjects: 64
Study 28678952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (S2)
Number of subjects: 64
Study 28678952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% R. communis (S3)
Number of subjects: 64
Study 28678952 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline, S4)
Number of subjects: 64
Study 28678952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (S1) and 0.5% sodium hypochlorite (S2)
Number of subjects: 64
Study 28678952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 64
Study 25196702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/d
Number of subjects: 502
Study 25196702 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 502
Study 23623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group A (test formulation)
Number of subjects: 102
Study 23623755 — intervention group
Group type: COMPARATOR
Intervention: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group B (reference formulation)
Number of subjects: 102
Study 23623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 102
Study 21527231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing and pelvic floor muscles (PFM) retraining in group A
Number of subjects: 86
Study 21527231 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy in group B
Number of subjects: 86
Study 21527231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received treatment for constipation and recurrent urinary tract infections (UTIs)
Number of subjects: 86
Study 21527231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received uroflowmetry with pelvic floor electromyography and ultrasound residual urine volumes
Number of subjects: 86
Study 18384519 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week treatment regimen of peginterferon and ribavirin
Number of subjects: 61
Study 18384519 — intervention group
Group type: COMPARATOR
Intervention: 24-week treatment regimen of peginterferon and ribavirin
Number of subjects: 61
Study 16996596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold grid laser treatment (SGLT)
Number of subjects: 36
Study 16996596 — intervention group
Group type: COMPARATOR
Intervention: Threshold grid laser treatment (TGLT)
Number of subjects: 36
Study 14966078 — intervention group
Group type: EXPERIMENTAL
Intervention: General leaflet
Number of subjects: 636
Study 14966078 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression leaflet
Number of subjects: 636
Study 14966078 — intervention group
Group type: COMPARATOR
Intervention: Neither leaflet
Number of subjects: 636
Study 10896845 — intervention group
Group type: EXPERIMENTAL
Intervention: Free nicotine patches plus proactive telephone peer support
Number of subjects: 214
Study 10896845 — intervention group
Group type: COMPARATOR
Intervention: Free nicotine patches only
Number of subjects: 214
Study 9084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemiparetic patients
Number of subjects: 15
Study 9084100 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemiparetic patients
Number of subjects: 15
Study 9084100 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study 8451961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ankle movement with weight bearing in an orthosis
Number of subjects: 40
Study 8451961 — intervention group
Group type: COMPARATOR
Intervention: Active ankle movement without weight bearing using a dorsal splint
Number of subjects: 40
Study 3090723 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (10 mg daily)
Number of subjects: 4
Study 3090723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31103640 — intervention group
Group type: EXPERIMENTAL
Intervention: Language control during cooperative picture-naming
Number of subjects: 13
Study 31103640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of cross‐language interference and interpersonal interference
Number of subjects: 13
Study 29703633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29)
Number of subjects: 61
Study 29703633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32)
Number of subjects: 61
Study 29703633 — intervention group
Group type: COMPARATOR
Intervention: Both groups (oral and IV iron)
Number of subjects: 61
Study 26187522 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise plus usual care
Number of subjects: 60
Study 26187522 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention plus usual care
Number of subjects: 60
Study 26187522 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and psycho-educational plus usual care
Number of subjects: 60
Study 26187522 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 60
Study 24000053 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH+ intervention (community-based care management by an advanced practice nurse, minimum of one visit/week for 12 months)
Number of subjects: 238
Study 22917853 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 (3.0 mg, supratherapeutic dose)
Number of subjects: 54
Study 22917853 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 54
Study 22917853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 54
Study 19825815 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 0
Study 19825815 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 0
Study 17828038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (200 mg of intravenous erythromycin twice daily + 10 mg of intravenous metoclopramide four times daily)
Number of subjects: 75
Study 17828038 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin alone (200 mg of intravenous erythromycin twice daily)
Number of subjects: 75
Study 17828038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 75
Study 17828038 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 75
Study 15142201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole in NaCl
Number of subjects: 65
Study 15142201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole in polyethylene glycol
Number of subjects: 65
Study 15142201 — intervention group
Group type: COMPARATOR
Intervention: Per oral lansoprazole
Number of subjects: 65
Study 15142201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 65
Study 11574346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90
Study 11574346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 90
Study 11574346 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90
Study 9757955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive reminder system (mail and telephone reminders)
Number of subjects: 0
Study 9757955 — intervention group
Group type: COMPARATOR
Intervention: Scheduled appointment reminders only
Number of subjects: 0
Study 8141443 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine
Number of subjects: 40
Study 8141443 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine
Number of subjects: 40
Study 2899588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg and piperacillin 4 g (3 doses)
Number of subjects: 53
Study 2899588 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 53
Study 4895339 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane (0.35%) in air
Number of subjects: 50
Study 4895339 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen (50%/50%)
Number of subjects: 50
Study 31678231 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 90
Study 29100829 — intervention group
Group type: EXPERIMENTAL
Intervention: ChronOS
Number of subjects: 30
Study 29100829 — intervention group
Group type: EXPERIMENTAL
Intervention: ChronOS and autogenous bone graft in a 1:1 ratio
Number of subjects: 30
Study 29100829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss
Number of subjects: 30
Study 29100829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss and autogenous bone graft in a 1:1 ratio
Number of subjects: 30
Study 29100829 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft alone
Number of subjects: 30
Study 28414583 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and behavioral therapy
Number of subjects: 179
Study 26377497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis session (10-min presurgery)
Number of subjects: 64
Study 26377497 — intervention group
Group type: COMPARATOR
Intervention: Control session (presurgery)
Number of subjects: 64
Study 23153598 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with patellar eversion
Number of subjects: 72
Study 23153598 — intervention group
Group type: COMPARATOR
Intervention: TKA without patellar eversion
Number of subjects: 72
Study 21822144 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 5 days
Number of subjects: 0
Study 21822144 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg single dose
Number of subjects: 0
Study 21822144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg single dose after 5 days of omeprazole
Number of subjects: 0
Study 19060642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Care (PCC)
Number of subjects: 116
Study 19060642 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 116
Study 16219327 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 52
Study 16219327 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 12667513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 10
Study 10670394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free infant formula
Number of subjects: 137
Study 10670394 — intervention group
Group type: COMPARATOR
Intervention: Lactose-containing infant formula
Number of subjects: 137
Study 9147709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg thrice daily
Number of subjects: 106
Study 9147709 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg once daily
Number of subjects: 106
Study 8365915 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological training program (part of a comprehensive rehabilitation program lasting over six months, consisting of four modules)
Number of subjects: 51
Study 8365915 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 51
Study 3921380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 2
Study 30481333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 150
Study 30481333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy (SRT)
Number of subjects: 150
Study 30481333 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 150
Study 29937273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 0
Study 29937273 — intervention group
Group type: COMPARATOR
Intervention: Statins plus Ezetimibe
Number of subjects: 0
Study 26866477 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parenting intervention
Number of subjects: 136
Study 26866477 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 136
Study 25332468 — intervention group
Group type: EXPERIMENTAL
Intervention: Leu-enriched essential amino acids (3.5 g of Leu)
Number of subjects: 15
Study 25332468 — intervention group
Group type: COMPARATOR
Intervention: Control essential amino acids (1.85 g of Leu)
Number of subjects: 15
Study 22779280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm post length
Number of subjects: 30
Study 22779280 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mm post length
Number of subjects: 30
Study 22779280 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mm post length
Number of subjects: 30
Study 20482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods involving self-poisoning, jumping or stabbing
Number of subjects: 70
Study 20482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower effectiveness of the DSH event to resolve the reasons for the event
Number of subjects: 70
Study 20482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Any method other than superficial external injury to skin
Number of subjects: 70
Study 18256393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 160
Study 18256393 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 160
Study 16749353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Peritoneal Dialysis (IPD)
Number of subjects: 40
Study 16749353 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 40
Study 12514650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1988 ACC/AHA guidelines for PTCA
Number of subjects: 1219
Study 12514650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1993 ACC/AHA guidelines for PTCA
Number of subjects: 1219